Release 4B

This page is part of the FHIR Specification (v4.3.0: R4B - STU). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B

15.5.7 Resource AdministrableProductDefinition - Mappings

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeSecurity Category: Anonymous Compartments: Not linked to any defined compartments

Mappings:

IDMP Mapping

Mappings for the administrableproductdefinition resource (see Mappings to Other Standards for further information & status).

15.5.7.1 IDMP Mapping (https://en.wikipedia.org/wiki/Identification_of_medicinal_products )

AdministrableProductDefinitionPharmaceutical Product
    identifiern/a
    statusn/a
    formOf(link to Medicinal Product)
    administrableDoseFormPharmaceutical Product.Administrable Dose Form
    unitOfPresentationPharmaceutical Product.Unit of Presentation
    producedFromn/a (this is the link from Pharmaceutical Product to the Manufactured Item(s))
    ingredientPharmaceutical Product.Ingredient (see also FHIR Ingredient resource)
    devicePharmaceutical Product.Device
    propertyPharmaceutical Product Characteristics
        typePharmaceutical Product Characteristics.Code System (not a one to one map, the resource is more capable)
        value[x]Pharmaceutical Product Characteristics.Value (not a one to one map, the resource is more capable)
        statusPharmaceutical Product Characteristics.Status
    routeOfAdministrationPharmaceutical Product.Route of Administration
        codeRoute of Administration.Route of Administration
        firstDoseDosing and Route of Administration.First dose in humans (Investigational Medicinal Product)
        maxSingleDoseDosing and Route of Administration.Maximum single dose (Investigational Medicinal Product)
        maxDosePerDayDosing and Route of Administration.Maximum dose per day (Investigational Medicinal Product)
        maxDosePerTreatmentPeriodDosing and Route of Administration.Maximum dose per treatment period (Investigational Medicinal Product)
        maxTreatmentPeriodDosing and Route of Administration.Maximum treatment period (Investigational Medicinal Product)
        targetSpeciesn/a
            coden/a
            withdrawalPeriodn/a
                tissuen/a
                valuen/a
                supportingInformationn/a